Cyberonics panel date finalized
This article was originally published in The Gray Sheet
Executive Summary
VNS vagus nerve stimulation therapy for depression will go before FDA's Neurological Devices Panel June 15, CDRH says, confirming company's announcement (1"The Gray Sheet" April 5, 2004, p. 8). A PMA supplement covers adjunctive treatment of chronic or recurrent depression for patients resistant to antidepressants...
You may also be interested in...
Cyberonics VNS Depression Treatment Panel Review Tentatively Set For June
FDA's Neurological Devices Advisory Panel will review a PMA supplement for Cyberonics' VNS Therapy depression indication June 15, the firm says
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.